7K. Br?sen,L. F. Gram. Clinical significance of the sparteine/debrisoquine oxidation polymorphism[J] 1989,European Journal of Clinical Pharmacology(6):537～547
8G. L. -Y. Chan,J. E. Axelson,J. D. E. Price,K. M. McErlane,C. R. Kerr. In vitro protein binding of propafenone in normal and uraemic human sera[J] 1989,European Journal of Clinical Pharmacology(5):495～499
9P. Giani,M. Landolina,V. Giudici,C. Bianchini,G. Ferrario,S. Marchi,E. Riva,R. Latini. Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration[J] 1988,European Journal of Clinical Pharmacology(2):187～194
10F. Wagner,E. J?hnchen,D. Trenk,M. Eichelbaum,P. Harnasch,G. Hauf,H. Roskamm. Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine[J] 1987,Klinische Wochenschrift(24):1164～1168
